Single dose captopril as a diagnostic test for primary aldosteronism

Area of Science:

• Endocrinology
• Hypertension Research
• Diagnostic Medicine

Background:

• Primary aldosteronism diagnosis often relies on extracellular fluid expansion to suppress the renin-angiotensin system.
• This suppression causes a drop in plasma aldosterone in normal subjects and essential hypertension (EH) patients, but not in primary aldosteronism patients.

Purpose of the Study:

• To evaluate captopril, an angiotensin II synthesis inhibitor, as a diagnostic test for primary aldosteronism.
• To assess plasma aldosterone concentrations and aldosterone-to-renin ratios after captopril administration.

Main Methods:

• Measured plasma aldosterone concentrations 2 hours post-25 mg captopril in 9 normotensive subjects, 10 EH patients, and 12 primary aldosteronism patients.
• Subjects maintained an unrestricted diet during the test.

Main Results:

• Plasma aldosterone decreased below 15 ng/dl in all normotensive subjects and 90% of EH patients.
• Aldosterone remained >15 ng/dl in 80% of idiopathic hyperaldosteronism and 100% of aldosterone-producing adenoma patients.
• An aldosterone to renin ratio >50 identified primary aldosteronism, while <50 was observed in normotensive and EH groups.

Conclusions:

• Captopril challenge is a valuable diagnostic tool for primary aldosteronism.
• A nomogram using plasma aldosterone and aldosterone-to-renin ratio effectively distinguishes primary aldosteronism from EH.